TransPharma Completes Phase 2 Trial For ViaDerm-hPTH(1-34)

TransPharma has reported the successful completion of the phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

Reportedly, in June 2008, Eli Lilly and TransPharma entered into a licensing and development agreement relating to TransPharma’s ViaDerm-hPTH(1-34) product for the treatment of severe osteoporosis. As part of the project, TransPharma has completed a three-month phase 2A trial for transdermal PTH(1-34).

The company said that the primary and secondary endpoints for efficacy and safety were met. The safety endpoints included a skin safety endpoint for repeated dosing with the ViaDerm system.

Moreover, the initiation of a dose-ranging phase 2B study to be jointly conducted by Eli Lilly and TransPharma is planned for later this year.

Daphna Heffetz, CEO of TransPharma, said: We are very pleased with the results of this trial, which demonstrate remarkable progress in the use of the ViaDerm system in clinical trials. We have met the primary and secondary endpoints of the phase 2A trial. We are looking forward to the phase 2B trial, and hope that, in the future, we will be able to improve therapy for people suffering from osteoporosis by offering an alternative to daily injection of PTH.”